Hangzhou, China
Innoforce Pharmaceuticals, founded in 2018, is expertly navigating the intersection of Biopharma, Biotechnology, and Pharmaceutical manufacturing. The company's slogan, "Empowering Advanced Therapeutics," encapsulates its mission to facilitate innovation and global supply of critical medical components such as plasmid DNA, RNA, and cell & gene therapeutics.
Headquartered in China, Innoforce boasts a sophisticated manufacturing and development hub that underscores its capabilities in the production of Advanced Therapy Medicinal Products (ATMPs). By offering a comprehensive service pipeline from R&D to commercialization, the company positions itself as an indispensable partner for innovators in the therapeutics landscape.
The company's growth is supported by a notable CNY375.00M Series A investment, finalized on 01 December 2021. This funding round saw participation from an impressive roster of investors, including AdvanTech Capital, Quan Capital, and Yanchuang Capital, among others, highlighting strong investor confidence in Innoforce Pharmaceuticals.
